Foundation Resource Management Inc. Sells 11,605 Shares of Sanofi (NASDAQ:SNY)

Foundation Resource Management Inc. trimmed its holdings in Sanofi (NASDAQ:SNY - Free Report) by 4.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 260,662 shares of the company's stock after selling 11,605 shares during the quarter. Sanofi accounts for 2.3% of Foundation Resource Management Inc.'s portfolio, making the stock its 16th largest holding. Foundation Resource Management Inc.'s holdings in Sanofi were worth $14,456,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Brighton Jones LLC raised its stake in shares of Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after purchasing an additional 1,869 shares in the last quarter. Yousif Capital Management LLC raised its stake in shares of Sanofi by 53.2% in the fourth quarter. Yousif Capital Management LLC now owns 59,611 shares of the company's stock valued at $2,875,000 after purchasing an additional 20,690 shares in the last quarter. Strategic Financial Concepts LLC acquired a new position in shares of Sanofi in the fourth quarter valued at $667,000. Apollon Wealth Management LLC raised its stake in shares of Sanofi by 8.8% in the fourth quarter. Apollon Wealth Management LLC now owns 17,865 shares of the company's stock valued at $862,000 after purchasing an additional 1,441 shares in the last quarter. Finally, Savant Capital LLC raised its stake in shares of Sanofi by 24.8% in the fourth quarter. Savant Capital LLC now owns 6,361 shares of the company's stock valued at $307,000 after purchasing an additional 1,264 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $50.47 on Monday. The business has a fifty day moving average of $51.71 and a 200-day moving average of $52.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The firm has a market cap of $123.78 billion, a PE ratio of 20.27, a price-to-earnings-growth ratio of 1.01 and a beta of 0.50. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The firm had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company's revenue was down 11.0% on a year-over-year basis. During the same period last year, the company earned $1.78 earnings per share. On average, equities research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a $2.0369 dividend. This represents a yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi's dividend payout ratio (DPR) is presently 57.14%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. BNP Paribas assumed coverage on Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Morgan Stanley set a $56.00 price objective on Sanofi in a research note on Monday, June 2nd. The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. Finally, Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three analysts have rated the stock with a hold rating, three have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.